CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Galantamine +1 moredrug
Likely dose
Galantamine 12 mg twice daily (maintenance) or Donepezil 10 mg twice daily (maintenance)AI-extracted
Key inclusion· 5
  • ✓Admitted to rehabilitation hospital with primary diagnosis of ischemic stroke
  • ✓Stroke occurred within 30 days of admission
  • ✓Medically stable at time of enrollment
  • ✓Presence of new or worsened memory and/or attentional impairments caused by the stroke
Key exclusion· 9
  • ✕Aphasia or cognitive/behavioral impairments severe enough to prevent valid neuropsychiatric assessment
  • ✕Currently experiencing untreated or inadequately treated major depressive episode
  • ✕Current psychosis or mania
  • ✕History of substance or alcohol abuse/dependence within 3 months of study entry

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00227994
NCT00227994Phase 4Completed
CompareCT.gov

Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly

University of Pittsburgh·interventional·Posted Sep 28, 2005·Updated Dec 11, 2017

In Brief

A Phase 4 clinical trial evaluating Galantamine and Donepezil for Cerebrovascular Accident. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebrovascular Accident
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2005
Enrollment StartApr 1, 2003
Primary CompletionJan 1, 2005
Study CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.8 years ago

Interventions

Galantaminedrug

Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.

Donepezildrug

Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.